• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.

作者信息

Olsen G D, Bennett W M, Porter G A

出版信息

Clin Pharmacol Ther. 1975 Jun;17(6):677-84. doi: 10.1002/cpt1975176677.

DOI:10.1002/cpt1975176677
PMID:1095281
Abstract

The binding of morphine and phenytoin to plasma proteins was examined in healthy subjects and in patients with renal and hepatic failure. In the uremic patients without hepatic failure, morphine binding was dependent on the concentration of total serum proteins and albumin, but not the severity of renal failure as measured by creatinine clearance. Binding of phenytoin, however, was dependent on the degree of renal failure and albumin concentration, but not on total serum protein concentration. Renal transplant in 1 patient restored the binding of both drugs to a value within the normal range. The combination of hypoalbuminemia and hyperbilirubinemia resulted in the greatest impairment to binding for both drugs. It is concluded that patients with uremia, jaundice, hypoalbuminemia, particularly in combination, are sensitive to usual clinical doses of morphine, at least in part, because of decreased binding to plasma proteins.

摘要

相似文献

1
Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
Clin Pharmacol Ther. 1975 Jun;17(6):677-84. doi: 10.1002/cpt1975176677.
2
Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
Clin Pharmacokinet. 1977 Mar-Apr;2(2):147-53. doi: 10.2165/00003088-197702020-00005.
3
Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation.肾移植术后患者苯妥英蛋白结合率与标准实验室参数的相关性及预测
Ther Drug Monit. 2001 Jun;23(3):263-7. doi: 10.1097/00007691-200106000-00014.
4
Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.尿毒症患者苯妥英钠的血浆蛋白结合受损及水杨酸的置换作用。
Clin Pharmacol Ther. 1976 Jul;20(1):36-47. doi: 10.1002/cpt197620136.
5
Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia.
Ther Drug Monit. 1988;10(4):376-81. doi: 10.1097/00007691-198804000-00002.
6
Plasma protein binding of thiopental in patients with impaired renal or hepatic function.肾功能或肝功能受损患者中硫喷妥钠的血浆蛋白结合情况。
Anesthesiology. 1975 May;42(5):545-9. doi: 10.1097/00000542-197505000-00007.
7
Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.苯妥英、地西泮和普萘洛尔在慢性肾脏疾病中的血清蛋白结合情况。
Int J Clin Pharmacol Ther Toxicol. 1987 Oct;25(10):545-52.
8
Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring.健康与疾病状态下苯妥英的血浆蛋白结合:与治疗药物监测的相关性
Ther Drug Monit. 1980;2(4):331-44.
9
Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
Clin Pharmacol Ther. 1981 Aug;30(2):276-80. doi: 10.1038/clpt.1981.159.
10
Plasma protein binding of azapropazone in patients with kidney and liver disease.阿扎丙宗在肾脏和肝脏疾病患者中的血浆蛋白结合情况。
Br J Clin Pharmacol. 1981 Apr;11(4):361-7. doi: 10.1111/j.1365-2125.1981.tb01133.x.

引用本文的文献

1
The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.以吗啡为例说明基于生理的药代动力学模型在法医学中的可行性。
Int J Legal Med. 2018 Mar;132(2):415-424. doi: 10.1007/s00414-017-1754-8. Epub 2017 Dec 1.
2
Cautious use and optimal dose of morphine for relieving malignant pain in a complex patient with multiple comorbidities.在一位患有多种合并症的复杂患者中谨慎使用吗啡并确定其缓解恶性疼痛的最佳剂量。
BMJ Case Rep. 2016 Dec 16;2016:bcr2016217174. doi: 10.1136/bcr-2016-217174.
3
Clinical Pharmacology Studies in Critically Ill Children.
危重症儿童的临床药理学研究
Pharm Res. 2017 Jan;34(1):7-24. doi: 10.1007/s11095-016-2033-y. Epub 2016 Sep 1.
4
Analgesics in patients with hepatic impairment: pharmacology and clinical implications.肝功能损害患者的镇痛药:药理学和临床意义。
Drugs. 2012 Aug 20;72(12):1645-69. doi: 10.2165/11635500-000000000-00000.
5
Differential kinetics of phenytoin in elderly patients.老年患者苯妥英钠的差异动力学
Drugs Aging. 1999 Sep;15(3):235-50. doi: 10.2165/00002512-199915030-00006.
6
Pharmacokinetics of opioids in liver disease.阿片类药物在肝脏疾病中的药代动力学。
Clin Pharmacokinet. 1999 Jul;37(1):17-40. doi: 10.2165/00003088-199937010-00002.
7
Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.接受吗啡治疗的癌症患者体内吗啡、吗啡 - 3 - 葡萄糖醛酸苷和吗啡 - 6 - 葡萄糖醛酸苷的血浆浓度及肾清除率
Clin Pharmacokinet. 1993 May;24(5):413-20. doi: 10.2165/00003088-199324050-00005.
8
Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.单次和多次给药后,肾或肝功能损害患者中丁螺环酮的处置动力学。
Eur J Clin Pharmacol. 1994;46(1):41-7. doi: 10.1007/BF00195914.
9
Alteration of drug-protein binding in renal disease.肾脏疾病中药物与蛋白质结合的改变。
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:18-26. doi: 10.2165/00003088-198400091-00003.
10
Anticonvulsant drugs. An update.抗惊厥药物。最新进展。
Drugs. 1984 Apr;27(4):328-63. doi: 10.2165/00003495-198427040-00003.